Abbvie’s Rinvoq matches BMS’ Orencia in head-to-head rheumatoid arthritis trial
With megablockbuster Humira on the decline, AbbVie is hoping for big things from its next-gen JAK inhibitor Rinvoq. Now, in a head-to-head rheumatoid arthritis battle with Bristol Myers Squibb’s blockbuster Orencia, Rinvoq has come out on top. Rinvoq matched Bristol’s Orencia in easing rheumatoid arthritis patients’ symptoms at the 12-week mark and bested its older rival in patient remission rates, according to… Read More »